Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Efficacy of Ibrexafungerp (IBX, formerly SCY-078) in the Treatment of Candida auris Cutaneous Infection in a Guinea Pig Model

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI study

Ibrexafungerp (formerly SCY-078) Demonstrates Activity Against Candida auris: In Vitro, In Vivo and Clinical Case Studies of Candidemia

Candida auris is Highly In Vitro Susceptible to Ibrexafungerp (formerly SCY-078) in EUCAST Antifungal Susceptibility Testing

Successful Treatment of a Patient with Retroperitoneal Abscess caused by Candida krusei with the Investigational Agent, Ibrexafungerp (formerly SCY-078): A Case Report from the FURI Study

In vitro Evaluation of Combination of Ibrexafungerp and Azoles against Aspergillus spp. Isolated from Lung Transplant Recipients

Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model

Delayed Initiation of the Novel Oral Glucan Synthase Inhibitor, Ibrexafungerp, is Effective in a Murine Model of Invasive Candidiasis caused by Candida auris